131 related articles for article (PubMed ID: 30873599)
1. Eltrombopag induces major non-toxic hypersiderraemia.
Caillon H; Peterlin P; Chevallier P; Guillaume T; Lebourgeois A; Garnier A; Ropert-Bouchet M; Dejoie T
Br J Haematol; 2019 Jul; 186(2):365-366. PubMed ID: 30873599
[No Abstract] [Full Text] [Related]
2. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Huan Ng C; Jang-Milligan F; Schultz KR
Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
[No Abstract] [Full Text] [Related]
3. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
Rivera D; Bastida JM; Lopez-Corral L; Sanchez-Guijo F; Cabrero M; Martin A; Perez E; Lopez-Parra M; Avendaño A; Veiga A; Baile M; Arratibel N; Carrillo J; Vazquez L; Caballero MD; Gonzalez-Porras JR
Bone Marrow Transplant; 2019 May; 54(5):757-761. PubMed ID: 30356164
[No Abstract] [Full Text] [Related]
4. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Masetti R; Vendemini F; Quarello P; Girardi K; Prete A; Fagioli F; Pession A; Locatelli F
Pediatr Blood Cancer; 2020 May; 67(5):e28208. PubMed ID: 32065469
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B; Levati G; Cassin R; Barcellini W
Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
Dickinson M; Cherif H; Fenaux P; Mittelman M; Verma A; Portella MSO; Burgess P; Ramos PM; Choi J; Platzbecker U;
Blood; 2018 Dec; 132(25):2629-2638. PubMed ID: 30305280
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
Paul S; Jain N; Ferrajoli A; O'Brien S; Burger J; Keating M; Wierda W
Br J Haematol; 2019 May; 185(3):606-608. PubMed ID: 30406944
[No Abstract] [Full Text] [Related]
9. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
[No Abstract] [Full Text] [Related]
10. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Scully M; Kaczmarski R; Myers B; Collins R; Emohare O; Bolton-Maggs PH
Br J Haematol; 2012 Apr; 157(2):259-60. PubMed ID: 22091659
[No Abstract] [Full Text] [Related]
11. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
12. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
[TBL] [Abstract][Full Text] [Related]
14. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
15. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629
[TBL] [Abstract][Full Text] [Related]
16. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Mulla CM; Rashidi A; Levitov AB
Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
[No Abstract] [Full Text] [Related]
17. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
18. An Eltrombopag Red (Plasma) Alert.
Al-Samkari H; Goodarzi K
Acta Haematol; 2021; 144(2):227-228. PubMed ID: 32702690
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag Add-on Treatment in a Child With Fanconi Aplastic Anemia Awaiting Hematopoietic Stem Cell Transplantation.
Aydin Koker S; Çalişkan Polat A
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e74-e76. PubMed ID: 33560087
[TBL] [Abstract][Full Text] [Related]
20. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
